BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (pros-CLOVES syndrome)
View Patent ↗The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) 10 syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the 15 two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.
1. A method of treating a subject having a PIK3CA-related overgrowth spectrum (PROS) disorder, comprising the steps of
identifying the subject as suffering from the PROS disorder and having an overgrowth of multiple organs or tissues caused by a somatic mosaic mutation;
administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is sufficient to treat said PROS disorder; and reverses said overgrowth of multiple organs or tissues, wherein said PROS disorder is not responsive to treatment with rapamycin.
2. The method of claim 1 , wherein the PROS disorder is Congenital Lipomatous Overgrowth, Vascular Malformation, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome.
3. The method of claim 1 , wherein the PROS disorder is Klippel-Trenaunay syndrome.
4. The method of claim 1 , wherein BYL719 is administered daily and the dose is in the range of 25 to 250 mg or in the range of 0.5 to 6 mg/kg.
5. The method of claim 1 , wherein the subject is an adult, and the therapeutically effective amount is a starting dose of at least 250 mg per day.
6. The method of claim 1 , wherein the subject is a child, and the therapeutically effective amount is a starting dose of at least 50 mg per day.
7. The method of claim 1 , wherein the subject is an infant, and the therapeutically effective amount is a starting dose of at least 25 mg per day.
8. A method of treating a plurality of symptoms of a PIK 3 CA-related overgrowth spectrum (PROS) disorder in an adult, child or infant suffering from a PROS disorder, comprising the steps of
identifying an adult, child or infant suffering from a PROS disorder causing the plurality of symptoms due to overgrowth of multiple organs or tissues,
administering orally to the subject with a therapeutically effective amount of BYL719 in the range of 15 to 500 mg or in the range of 0.3 to 12 mg/kg, and
reversing the plurality of symptoms due to overgrowth of multiple organs or tissues, wherein the plurality of symptoms are selected from the group consisting of paraplegia, loss of bladder control, edema, enlarged circumference of thorax and abdomen, venous dilation, vascular tumors, elevated brain natriuretic peptide blood level, proteinuria, kidney dysfunction, cardiac enlargement, cardiac dysfunction, overgrown tissue, limb hypertrophy, dysregulated adipose tissue, scoliosis, enlarged bony structures without progressive bony overgrowth, benign tumors, megalencephaly-capillary malformation, lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, epidermal nevi, lymphatic malformation, muscle hypertrophy, kidney dysfunction, liver steatosis and spleen disorganization, and wherein the PROS disorder is selected from the group consisting of
fibroadipose overgrowth;
megalencephaly-capillary malformation syndrome;
congenital lipomatous asymmetric overgrowth, lymphatic capillary, venous and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome;
hemihyperplasia multiple lipomatosis; and
Klippel-Trenaunay syndrome, and
wherein said PROS disorder is not responsive to treatment with rapamycin.
9. The method of claim 4 , wherein the subject is an adult, and the therapeutically effective amount is a starting dose of at least 250 mg per day.
10. The method of claim 4 , wherein the subject is a child, and the therapeutically effective amount is a starting dose of at least 50 mg per day.
11. The method of claim 4 , wherein the subject is an infant and the therapeutically effective amount is a starting dose of at least 25 mg per day.
12. The method of claim 8 , wherein the PROS disorder is CLOVES syndrome.
13. The method of claim 8 , wherein the PROS disorder is Klippel-Trenaunay syndrome.
14. A method of treating a patient who is an adult having a PIK3CA-related overgrowth spectrum (PROS) disorder caused by a somatic mosaic mutation, comprising the steps of
identifying the subject as suffering from the PROS disorder of an overgrowth of multiple organs or tissues;
administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 250 mg daily; and
reversing the overgrowth of multiple organs or tissues;
wherein said PROS disorder is not responsive to treatment with rapamycin.
15. A method of treating a patient who is a child having a PIK3CA-related overgrowth spectrum (PROS) disorder caused by a somatic mosaic mutation, comprising the steps of
identifying the subject as suffering from the PROS disorder of an overgrowth of multiple organs or tissues;
administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 50 mg daily; and
reversing the overgrowth of multiple organs or tissues;
wherein said PROS disorder is not responsive to treatment with rapamycin.
16. The method of claim 1 , wherein the therapeutically effective amount of BYL719 is in the range of 15 to 500 mg or the range of 0.3 to 12 mg/kg.